ONCOSYNE AS
Operating
Forskning og utviklingsarbeid innen medisinsk bioteknologi med det
formål å tilby legemiddelscreening som en diagnostisk tjeneste.
Legemiddelscreenen skal være et beslutningsverktøy for skånsom, presis
og effektiv kreftbehandling.
Forskning og utviklingsarbeid innen medisinsk bioteknologi med det
formål å tilby legemiddelscreening som en medisinsk
laboratorietjeneste.
Organization
- Chairman of the board
- PA
- Years since formation
- 5 years
- since Dec 16, 2020
- Type
- Limited company
- VAT registered
- Yes
- Number of employees
- 0
Ownership
- Number of shares and share classes
- 1,124,801
- 1 share class
- Total number of shareholders
- 13
- 11 companies, 2 persons
Financials
- Total operating income 2024
- 4,379,980
- NOK
- Annual total result 2024
- -1,721,316
- NOK
- Total equity 2024
- 10,761,782
- NOK
Last update: Sep 9, 2025
Management
Board
| Name | Role | Shares |
|---|---|---|
PA | Chairman | 31.12 % indirectly |
JM | Board Member | - |
JE | Board Member | 6.41 % indirectly |
SW 1948 | Board Member | 1.54 % indirectly |
BT | Observer | - |
BO 1961 | Board Member | - |
Others
| Name | Role | Shares |
|---|---|---|
| Accountant | - |
Top 10 individual shareholders
| Name | Role | Shares |
|---|---|---|
PA | Chairman | 31.12 % indirectly |
JB 1977 | - | 31.12 % indirectly |
JE | Board Member | 6.41 % indirectly |
JI | - | 4.17 % indirectly |
KF | - | 2.41 % indirectly |
SJ | - | 2.41 % indirectly |
| - | 2.41 % indirectly | |
HJ | - | 1.91 % indirectly |
JS 1970 | - | 1.84 % directly |
JA | - | 1.67 % indirectly |
Last update: Aug 15, 2025
Ownership
Company shareholders
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| Ordinary shares | 350,000 | 31.12 % | |
| Ordinary shares | 350,000 | 31.12 % | |
| Ordinary shares | 98,753 | 8.78 % | |
| Ordinary shares | 71,395 | 6.35 % | |
| Ordinary shares | 66,752 | 5.93 % | |
| Ordinary shares | 46,917 | 4.17 % | |
| Ordinary shares | 38,350 | 3.41 % | |
| Ordinary shares | 28,222 | 2.51 % | |
| Ordinary shares | 20,734 | 1.84 % | |
JS 1970 | Ordinary shares | 20,734 | 1.84 % |
| Ordinary shares | 18,814 | 1.67 % | |
MB | Ordinary shares | 10,368 | 0.92 % |
| Ordinary shares | 3,762 | 0.33 % |
Last update: Jun 2, 2025
Financials
in NOK
Summary
| Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total operating income | 4,379,980 | 1,656,989 | 1,450,000 | 450,000 |
Annual Total Result | -1,721,316 | -3,140,780 | -1,280,781 | -195,802 |
Total assets | 11,963,858 | 5,802,910 | 4,914,137 | 804,442 |
Total liabilities | 1,202,076 | 605,872 | 576,303 | 185,814 |
Total equity | 10,761,782 | 5,197,039 | 4,337,834 | 618,628 |
P&L
| Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total operating income | 4,379,980 | 1,656,989 | 1,450,000 | 450,000 |
Total operating costs | 6,361,033 | 4,843,673 | 2,742,102 | 651,769 |
Operating result | -1,981,054 | -3,186,683 | -1,292,102 | -201,769 |
Financial income/costs | 259,738 | 45,903 | 11,320 | 5,967 |
Profit before tax | -1,721,316 | -3,140,780 | -1,280,781 | -195,802 |
Total tax & extraordinary income/cost | 0 | 0 | 0 | 0 |
Annual Total Result | -1,721,316 | -3,140,780 | -1,280,781 | -195,802 |
Balance overview
| Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total fixed assets | 856,717 | 84,859 | 79,623 | 0 |
Total current assets | 11,107,141 | 5,718,052 | 4,834,514 | 804,442 |
Total assets | 11,963,858 | 5,802,910 | 4,914,137 | 804,442 |
Short term debt | 1,202,076 | 605,872 | 576,303 | 185,814 |
Long term debt | 0 | 0 | 0 | 0 |
Total liabilities | 1,202,076 | 605,872 | 576,303 | 185,814 |
Contributed capital | 17,100,461 | 9,814,402 | 5,814,417 | 814,430 |
Retained earnings | -6,338,679 | -4,617,363 | -1,476,583 | -195,802 |
Total equity | 10,761,782 | 5,197,039 | 4,337,834 | 618,628 |
Total equity and liabilities | 11,963,858 | 5,802,910 | 4,914,137 | 804,442 |
Classification
21st company classification
BETA
Small company
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises